
Nkarta, Inc. (NKTX) Stock Forecast & Price Target
Nkarta, Inc. (NKTX) Analyst Ratings
Bulls say
Nkarta is well positioned because NKX019 is showing early efficacy in autoimmune disease that appears comparable to CAR-T benchmarks, with 83% of IIM patients and 86% of SSc patients achieving meaningful responses at the 4B cell dose. The safety profile is a major differentiator, as across 40 AID patients no CRS, ICANS, IEC-HS, or GvHD were observed, supporting the potential for outpatient use and broader adoption. Fundamentally, the company also has a scalable off-the-shelf NK-cell platform, a deep pipeline opportunity in large U.S. markets, and management’s plan to optimize dosing up to 6B cells while targeting launch in 2031.
Bears say
Nkarta is a clinical-stage company with all of its programs still in Phase I, leaving its pipeline highly exposed to clinical failure, weak efficacy, or insufficient durability, and there is no assurance it can produce additional successful candidates from its NK cell platform or Crispr collaboration. Its commercial case is further weakened by intense competition in IIM and SSc, while no NK cell therapies have been approved by the FDA or EMA to date, creating substantial regulatory uncertainty and a long path to market with no guarantee of share capture. Financially, the company is likely to need additional funding to advance trials and eventual launch, and the risk of unfavorable financing, dilution, manufacturing setbacks, and a modeled 30% probability of success for NKX019 underscores a fragile risk-reward profile.
This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction
Start investing in Nkarta, Inc. (NKTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Nkarta, Inc. (NKTX) Forecast
Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction
Start investing in Nkarta, Inc. (NKTX)
Order type
Buy in
Order amount
Est. shares
0 shares